Semnur Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $98.30M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Semnur Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Semnur Pharmaceuticals filed with the SEC
Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex Holding Company, Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX,
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) Announces Signing
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Unaudited Condensed Balance Sheets as of June 30, 2025 and December 31, 2024
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
PRESS RELEASE, DATED JUNE 11, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 9, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 14, 2025
Shareholder vote results · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MARCH 11, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 11, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 8, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED DECEMBER 11, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 11, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED OCTOBER 11, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 11, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 3, 2024
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 9, 2024
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 10, 2024
Material agreement · New financial obligation · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 2, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 27, 2024
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED DECEMBER 29, 2023
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED OCTOBER 11, 2023
Material agreement · New financial obligation · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION DATED AUGUST 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Denali Capital Acquisition Corp. Announces Extension of Deadline
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Denali Capital Acquisition Corp. Announces Extension
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Longevity Biomedical Longer, Healthier Lives January 2023
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K/A
Longevity Biomedical, Inc. and Denali Capital Acquisition
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Denali Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing May 31, 2022.
Other events · EX-99.1 to Form 8-K
Audited Financial Statement of Denali Capital Acquisition Corp.:
Other events · EX-99.1 to Form 8-K
Denali Capital Acquisition Corp. Announces Pricing of $75 Million Initial Public Offering
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K